Free Trial

Tharimmune (THAR) Competitors

Tharimmune logo
$1.76 0.00 (0.00%)
Closing price 03:50 PM Eastern
Extended Trading
$1.79 +0.03 (+1.65%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

THAR vs. BIVI, RVPH, CING, JATT, MTEX, QTTB, MRKR, LPCN, CARM, and PRPH

Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include BioVie (BIVI), Reviva Pharmaceuticals (RVPH), Cingulate (CING), JATT Acquisition (JATT), Mannatech (MTEX), Q32 Bio (QTTB), Marker Therapeutics (MRKR), Lipocine (LPCN), Carisma Therapeutics (CARM), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry.

Tharimmune vs. Its Competitors

BioVie (NASDAQ:BIVI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 865.91%. Given Tharimmune's higher possible upside, analysts clearly believe Tharimmune is more favorable than BioVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioVie
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Tharimmune
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

BioVie is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/A-$32.12M-$7.91-1.02
TharimmuneN/AN/A-$12.20M-$7.88-0.22

In the previous week, BioVie had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Tharimmune. BioVie's average media sentiment score of 0.86 beat Tharimmune's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Positive
Tharimmune Neutral

BioVie's return on equity of -100.88% beat Tharimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
BioVieN/A -100.88% -78.49%
Tharimmune N/A -489.33%-264.34%

BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

4.6% of BioVie shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 2.4% of BioVie shares are held by insiders. Comparatively, 10.0% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioVie beats Tharimmune on 7 of the 13 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THAR vs. The Competition

MetricTharimmuneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.68M$2.90B$5.51B$8.96B
Dividend YieldN/A2.44%5.25%4.02%
P/E Ratio-0.2221.0128.0520.16
Price / SalesN/A295.02438.35127.91
Price / CashN/A41.8337.0657.97
Price / Book2.597.868.125.62
Net Income-$12.20M-$54.95M$3.16B$248.50M
7 Day Performance-3.30%6.24%4.40%5.54%
1 Month Performance10.00%5.70%4.09%7.52%
1 Year Performance-49.86%8.08%34.53%22.06%

Tharimmune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THAR
Tharimmune
2.7736 of 5 stars
$1.76
flat
$17.00
+865.9%
-48.8%$4.68MN/A-0.222
BIVI
BioVie
0.7083 of 5 stars
$0.99
+5.8%
N/A+111.8%$18.29MN/A-0.1210News Coverage
RVPH
Reviva Pharmaceuticals
2.2824 of 5 stars
$0.38
+2.9%
$9.00
+2,268.4%
-69.4%$18.24MN/A-0.485
CING
Cingulate
2.9214 of 5 stars
$4.27
+3.1%
$26.00
+508.9%
+1,135.6%$18.15MN/A-0.5020News Coverage
Positive News
JATT
JATT Acquisition
N/A$1.05
flat
N/A-67.7%$18.11MN/A0.003Gap Up
High Trading Volume
MTEX
Mannatech
0.2856 of 5 stars
$9.45
+2.9%
N/A+17.5%$17.96M$117.87M-94.50250Gap Up
QTTB
Q32 Bio
2.0324 of 5 stars
$1.46
+1.7%
$12.17
+731.1%
-92.7%$17.81M$1.16M-0.3039
MRKR
Marker Therapeutics
3.667 of 5 stars
$1.57
+4.0%
$13.17
+738.6%
-65.6%$17.76M$6.59M-1.1860Positive News
LPCN
Lipocine
1.554 of 5 stars
$3.21
+0.5%
$9.00
+180.8%
-57.8%$17.15M$11.20M-3.1410
CARM
Carisma Therapeutics
2.3948 of 5 stars
$0.41
+0.5%
$1.93
+373.0%
-66.2%$17.05M$19.63M-0.2620
PRPH
ProPhase Labs
N/A$0.40
+5.0%
N/A-87.1%$16.66M$6.77M-0.32130

Related Companies and Tools


This page (NASDAQ:THAR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners